Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
NIH supports development, testing, and clinical feasibility studies of therapeutic and diagnostic devices for nervous or neuromuscular disorders through milestone-driven cooperative agreements.
This grant was recently updated
This grant has transitioned from forecasted to posted and is now accepting applications.
Funder: National Institutes of Health
Due Dates: January 28, 2027 (Application) | May 28, 2027 (Application) | September 28, 2027 (Application) | January 28, 2028 (Final application deadline)
Funding Amounts: No fixed budget limit; up to 5 years total across UG3 and UH3 phases; no cost sharing required
Summary: Supports translational device development and clinical feasibility studies for disorders affecting the nervous or neuromuscular systems.
Key Information: All projects must propose both UG3 development and UH3 clinical-study phases, with milestone-based NIH go/no-go decisions.
Description
NIH Blueprint MedTech supports investigators translating novel therapeutic and diagnostic medical devices toward clinical use. This milestone-driven cooperative agreement funds clinical prototypes, nonclinical safety and efficacy testing, design verification and validation, and regulatory activities leading to clinical feasibility studies. Clinical studies should answer questions about device function or final design that cannot practically be resolved through further bench or animal testing.
The program combines funding for work within the applicant’s organization with NIH-funded consultants and specialized research services. These resources help address regulatory strategy, reimbursement, intellectual property, commercialization, manufacturing, testing, and clinical-study needs. The goal is to accelerate patient access to safe, effective devices and reduce development risk sufficiently to attract further investment. Projects must align with participating NIH institute and center missions; institute-specific interests and clinical-study limitations also apply.
